Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis
Sponsor: Chulalongkorn University
Summary
Patients with severe hemophilia A often develop joint complication requiring careful monitoring. This study aimed to compare the effectiveness of standard low dose weight-based FVIII concentrates (CFCs) prophylaxis with pharmacokinetic-guided extended half-life FVIII concentrates (eHLFVIII) using cartilage biomarkers and HEAD-US score.
Official title: Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving Low Dose FVIII Prophylaxis
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
19
Start Date
2024-04-01
Completion Date
2025-02-28
Last Updated
2025-02-10
Healthy Volunteers
No
Conditions
Interventions
HEAD-US
HEAD-US for evaluate haemophilic arthropathy in 6 joints. (Elbow, Knee, Ankle)
Urinary carboxy-terminal cross linked telopeptide of type II collagen
Cartilage biomarker represent cartilage degradation
Inflammatory markers
Inflammatory markers included CBC, Ferritin, ESR, CRP
Locations (1)
Pediatric Department, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital
Bangkok, Patumwan, Thailand